EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Poll|February 5, 2015
1-Year-Old With "Bullseye" Rash
Author(s)ReelDx
This afebrile baby presents with a target-shaped, centripetal rash. He has been taking amoxicillin for 5 days for an ear infection.
Advertisement
This afebrile baby presents with a target-shaped, centripetal rash. He has been taking amoxicillin for 5 days for an ear infection.
What’s your impression?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
2
Elinzanetant Linked to Broad Improvements in Sleep Disturbance in Women With Moderate-to-Severe Vasomotor Symptoms
3
AI-Enhanced Virtual Reality Program Delivering CBT Shows Early Feasibility for Menopause Symptoms: TMS 2026
4
Long-Acting Injectable HIV PrEP: Efficacy, Safety, and Injection Reactions
5